Smith & Nephew (SNN) Q2 2026 Earnings Call Transcript
Smith & Nephew (SNN) reported Q2 2026 revenue of $1.6B, up 1.6% underlying and 2.8% reported, with FX adding 120 bps. U.S. revenue fell 1.3%, while emerging markets rose 10.6%. Half-year revenue was $3.1B. Trading profit rose $43M to $566M; gross margin was 71.1%.
How this was made
The 30-second read
Why it matters
The most tradable elements are the quantified profit headwinds tied to China VBP implementation and reimbursement-driven friction in skin substitutes/SANTYL, alongside reported margin and trading profit improvements.
Market read
Traders can update near-term earnings expectations around reimbursement reforms and China VBP timing, while also weighing cost savings and Sports Medicine momentum.
What to watch
Orthopaedics weakness is tied to mix, comparator effects, and deployment timing (CATALYSTEM set deployments), which could mean the near-term earnings risk is more timing-driven than structural.
Background
The article is a transcript of Smith & Nephew’s Q2 2026 earnings call, covering revenue by geography and business unit, plus margin and profit drivers.
Ticker impact
Smith & Nephew reports Q2 2026 results and updates segment drivers, including China VBP profit headwind of $15m to $20m and skin substitutes headwind near the top of $20m to $40m.
Likely choppy post-call trading, with downside risk if investors focus on the upper-end profit headwinds despite reported margin and trading profit improvement.
The transcript provides multiple quantified headwinds and margin/trading profit figures, but it is a call transcript rather than a standalone earnings release with full consensus context.
Market effects
Orthopaedics and wound-care reimbursement dynamics (CMS, payer prior authorization) remain a key swing factor for medtech earnings quality.
China inventory actions ahead of VBP and the expected VBP profit headwind can influence regional medtech sentiment and read-across for peers exposed to similar reimbursement reforms.
Margin expansion from manufacturing/procurement efficiency and tariff refunds highlights cost discipline as a counterweight to demand and reimbursement volatility.
Counterpoint
Investors may underweight the headwinds because the company frames underlying demand as healthy and expects SANTYL and skin substitutes to reaccelerate in the second half.
Key entities
- companySmith & Nephew
Reports Q2 2026 performance and provides quantified headwinds for China VBP and skin substitutes reimbursement impacts.
